The Government of Javier Milei announced a projected private investment of USD 8 billion aimed at the development of clinical research in Argentina, during a meeting with the Minister of Health, Mario Lugones, and representatives of the Argentine Chamber of Medicinal Specialties (CAEMe).
The announcement was made during a meeting attended by authorities from the main international laboratories present in the country, as part of an investment commitment that will unfold over the next six years.
Among those present were the president of CAEMe, Gastón Domingues Caetano, along with executives from leading companies in the sector: Carlos Annes (MSD), María Pía Orihuela (Roche), Silvana Kurkdjian (Bristol Myers Squibb), Francisco García (Novartis), Maximiliano Gutiérrez (GSK), Carolina López Camelo (Sanofi), and Agustina Ruiz Villamil (Pfizer).
The agreement establishes that the laboratories associated with CAEMe will promote a USD 8 billion investment in clinical research, in an initiative aimed at strengthening local scientific development and consolidating Argentina as a relevant player in global health innovation.
According to the details provided, this activity already represents nearly 50% of the total private investment in research and development (R&D) from the Argentine business sector, with a dominant participation from CAEMe members, who contribute 95% of that total.
